Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, today announced that the U.S.

With dose optimization complete and regulatory engagement underway, Bioxytran believes it has established the scientific and clinical foundation necessary to proceed into a pivotal Phase 3 ...

CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical ...

In modern information technology, the efficient and dynamic manipulation of these light "codes" is key to achieving ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

Nuclear magnetic resonance –based co-magnetometers are essential tools for applications ranging from inertial navigation to geophysical exploration and biomedical sensing. Their performance critically ...

DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

In power distribution systems, three-phase transformer configuration directly impacts system reliability and load management. Understanding the trade-offs between Delta and Wye connections enables ...

Researchers have made a major advance in quantum computing with a new device that is nearly 100 times smaller than the diameter of a human hair. Published in the journal Nature Communications, the ...